Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trilaciclib + Docetaxel in 2nd Line+ NSCLC
NCT06929936Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- May 2025
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trilaciclib in myelosuppression, sponsored by First Affiliated Hospital of Xiamen University. Started May 2025; status: recruiting.
02
Drugs
trilaciclib
03
Conditions
myelosuppression
Beyond the preview
Go deeper on NCT06929936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929936.